Alnylam Pharmace. buy Oppenheimer Holdings Inc.
Start price
07.01.26
/
50%
€361.70
Target price
07.01.27
€427.30
Performance (%)
-5.34%
Price
09.01.26
€342.40
Summary
This prediction is currently active. With a performance of -5.34%, the BUY prediction by Oppenheimer_Holdings is trending in the wrong direction. This prediction currently runs until 07.01.27. The prediction end date can be changed by Oppenheimer_Holdings at any time. Oppenheimer_Holdings has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Alnylam Pharmace. | -5.34% |
| iShares Core DAX® | 3.002% |
| iShares Nasdaq 100 | 2.966% |
| iShares Nikkei 225® | 5.606% |
| iShares S&P 500 | 2.312% |
Comments by Oppenheimer_Holdings for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (NASDAQ:ALNY) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $500.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Oppenheimer_Holdings for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€359.70
04.08.25
04.08.25
€423.31
04.08.26
04.08.26
-4.81%
09.01.26
09.01.26
